The TP53 Apoptotic Network is a Primary Mediator of Resistance to BCL2 inhibition in AML Cells

To study mechanisms underlying resistance to the BCL2 inhibitor, venetoclax, in acute myeloid leukemia (AML), we used a genome-wide CRISPR/Cas9 screen to identify gene knockouts resulting in drug resistance. We validated TP53, BAX, and PMAIP1 as genes whose inactivation results in venetoclax resista...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Discov
Autori principali: Nechiporuk, Tamilla, Kurtz, Stephen E., Nikolova, Olga, Liu, Tingting, Jones, Courtney L., D'Alessandro, Angelo, Culp-Hill, Rachel, d'Almeida, Amanda, Joshi, Sunil K., Rosenberg, Mara, Tognon, Cristina E., Danilov, Alexey V., Druker, Brian J., Chang, Bill H., McWeeney, Shannon K, Tyner, Jeffrey W.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2019
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6606338/
https://ncbi.nlm.nih.gov/pubmed/31048320
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-19-0125
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi